Comparison of the pharmacokinetics of sulfamethoxazole in male chinese volunteers at low altitude and acute exposure to high altitude versus subjects living chronically at high altitude: An open-label, controlled, prospective study

Background: Sulfamethoxazole is an antibacterial sulfonamide used primarily for the treatment of a wide variety of bacterial infections in combination with trimethoprim. Despite being used as prophylactic treatment for respiratory infections associated with high altitude, little information is avail...

Full description

Saved in:
Bibliographic Details
Published inClinical therapeutics Vol. 31; no. 11; pp. 2744 - 2754
Main Authors Li, Xiang-Yang, Gao, Fen, Li, Zhan-Quan, Guan, Wei, Feng, Wei-Li, Ge, Ri-Li
Format Journal Article
LanguageEnglish
Published Bridgewater, NJ EM Inc USA 01.11.2009
Elsevier
Elsevier Limited
Subjects
Online AccessGet full text
ISSN0149-2918
1879-114X
1879-114X
DOI10.1016/j.clinthera.2009.11.019

Cover

Abstract Background: Sulfamethoxazole is an antibacterial sulfonamide used primarily for the treatment of a wide variety of bacterial infections in combination with trimethoprim. Despite being used as prophylactic treatment for respiratory infections associated with high altitude, little information is available on the pharmacokinetic properties of sulfamethoxazole in subjects living at high altitude, especially in a Chinese population. Objective: This study was conducted to investigate the pharmacokinetics of sulfamethoxazole in healthy Chinese subjects after acute and chronic exposure to high altitude. Methods: An open-label, controlled, prospective study was conducted in healthy Chinese male volunteers. Sulfamethoxazole 1200 mg was administered orally to volunteers in 3 groups: those residing at low altitude (~400 m [~1300 ft]); these same volunteers after 16 hours (acute) of exposure to high altitude (~3780 m [~12,400 ft]); and a separate group of volunteers who had been living at high altitude (~3780 m) for ≥1 year (chronic). The phases of the low-altitude and acute-exposure groups were separated by a 1-week washout period. Blood samples were collected from an indwelling venous catheter into heparinized tubes before (baseline) study drug administration and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, and 48 hours after study drug administration. Sulfamethoxazole in whole blood, plasma, and plasma water, and its metabolite, N 4-acetyl-sulfamethoxazole, in plasma were determined by HPLC. Tolerability was determined using blood chemistry testing, continuous 12-lead ECG, and blood pressure monitoring. Results: A total of 23 healthy Chinese male volunteers living at low altitude (race, all Han Chinese; mean [SD] age, 20.4 [1.1] years [range, 19–24 years]; weight, 64.2 [5.9] kg [range, 56.0–75.0 kg]; and height, 172.1 [4.9] cm [range, 163.0–180.0 cm]) and 21 healthy Chinese male volunteers living at high altitude (race, all Han Chinese; mean [SD] age, 21.2 [1.3] years [range, 19–24 years]; weight, 62.4 [8.2] kg [range, 50.0–75.0 kg]; and height, 171.4 [5.8] cm [range, 162.0–182.0 cm]) were enrolled in the study; 20 from each group completed the study. Concentration of sulfamethoxazole in plasma water decreased significantly after exposure to high altitude; therefore, the protein binding was significantly higher in the acute- (80.4%) and chronic-exposure (72.5%) groups compared with the low-altitude group (65.7%; both, P < 0.001). The binding of sulfamethoxazole to red blood cells was 6.0%, 6.9%, and 9.3% in the low-altitude, acute-, and chronic-exposure groups, respectively. The chronic-exposure group was 55% higher than the low-altitude group ( P < 0.001). The following values were recorded in the low-altitude, acute-, and chronic-exposure groups after administration of sulfamethoxazole, respectively: mean (SD) t ½, 9.30 (1.11), 10.37 (0.88), and 11.15 (1.53) hours; mean residence time (MRT 0–48), 12.06 (0.94), 13.15 (0.67), and 13.00 (1.01) hours; elimination rate constant (k e), 0.076 (0.010), 0.067 (0.006), and 0.063 (0.009) hours −1; AUC 0–48, 1202.5 (238.3), 1416.3 (202.6), and 1298.5 (256.0) μ/mL/h; and clearance (CL), 1.01 (0.22), 0.83 (0.13), and 0.92 (0.22) L/kg/h. The t ½ was 11.5% and 19.9% higher in the acute- and chronic-exposure groups, respectively, compared with the low-altitude group, and 7.5% higher in the chronic-exposure group than in the acute-exposure group. MRT was 9.0% and 7.8% higher in the acute- ( P < 0.05) and chronic-exposure ( P < 0.001) groups, respectively, than in the low-altitude group. AUC 0–48 was 17.8% higher and CL was 17.8% lower in the acute-exposure group compared with the low-altitude group (both, P < 0.05). Conclusion: This study found significant changes in the disposition of sulfamethoxazole in these healthy male Chinese subjects after either acute or chronic exposure to an altitude of ~3780 m in comparison to those residing at an altitude of ~400 m.
AbstractList Background: Sulfamethoxazole is an antibacterial sulfonamide used primarily for the treatment of a wide variety of bacterial infections in combination with trimethoprim. Despite being used as prophylactic treatment for respiratory infections associated with high altitude, little information is available on the pharmacokinetic properties of sulfamethoxazole in subjects living at high altitude, especially in a Chinese population. Objective: This study was conducted to investigate the pharmacokinetics of sulfamethoxazole in healthy Chinese subjects after acute and chronic exposure to high altitude. Methods: An open-label, controlled, prospective study was conducted in healthy Chinese male volunteers. Sulfamethoxazole 1200 mg was administered orally to volunteers in 3 groups: those residing at low altitude (~400 m [~1300 ft]); these same volunteers after 16 hours (acute) of exposure to high altitude (~3780 m [~12,400 ft]); and a separate group of volunteers who had been living at high altitude (~3780 m) for ≥1 year (chronic). The phases of the low-altitude and acute-exposure groups were separated by a 1-week washout period. Blood samples were collected from an indwelling venous catheter into heparinized tubes before (baseline) study drug administration and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, and 48 hours after study drug administration. Sulfamethoxazole in whole blood, plasma, and plasma water, and its metabolite, N 4-acetyl-sulfamethoxazole, in plasma were determined by HPLC. Tolerability was determined using blood chemistry testing, continuous 12-lead ECG, and blood pressure monitoring. Results: A total of 23 healthy Chinese male volunteers living at low altitude (race, all Han Chinese; mean [SD] age, 20.4 [1.1] years [range, 19–24 years]; weight, 64.2 [5.9] kg [range, 56.0–75.0 kg]; and height, 172.1 [4.9] cm [range, 163.0–180.0 cm]) and 21 healthy Chinese male volunteers living at high altitude (race, all Han Chinese; mean [SD] age, 21.2 [1.3] years [range, 19–24 years]; weight, 62.4 [8.2] kg [range, 50.0–75.0 kg]; and height, 171.4 [5.8] cm [range, 162.0–182.0 cm]) were enrolled in the study; 20 from each group completed the study. Concentration of sulfamethoxazole in plasma water decreased significantly after exposure to high altitude; therefore, the protein binding was significantly higher in the acute- (80.4%) and chronic-exposure (72.5%) groups compared with the low-altitude group (65.7%; both, P < 0.001). The binding of sulfamethoxazole to red blood cells was 6.0%, 6.9%, and 9.3% in the low-altitude, acute-, and chronic-exposure groups, respectively. The chronic-exposure group was 55% higher than the low-altitude group ( P < 0.001). The following values were recorded in the low-altitude, acute-, and chronic-exposure groups after administration of sulfamethoxazole, respectively: mean (SD) t ½, 9.30 (1.11), 10.37 (0.88), and 11.15 (1.53) hours; mean residence time (MRT 0–48), 12.06 (0.94), 13.15 (0.67), and 13.00 (1.01) hours; elimination rate constant (k e), 0.076 (0.010), 0.067 (0.006), and 0.063 (0.009) hours −1; AUC 0–48, 1202.5 (238.3), 1416.3 (202.6), and 1298.5 (256.0) μ/mL/h; and clearance (CL), 1.01 (0.22), 0.83 (0.13), and 0.92 (0.22) L/kg/h. The t ½ was 11.5% and 19.9% higher in the acute- and chronic-exposure groups, respectively, compared with the low-altitude group, and 7.5% higher in the chronic-exposure group than in the acute-exposure group. MRT was 9.0% and 7.8% higher in the acute- ( P < 0.05) and chronic-exposure ( P < 0.001) groups, respectively, than in the low-altitude group. AUC 0–48 was 17.8% higher and CL was 17.8% lower in the acute-exposure group compared with the low-altitude group (both, P < 0.05). Conclusion: This study found significant changes in the disposition of sulfamethoxazole in these healthy male Chinese subjects after either acute or chronic exposure to an altitude of ~3780 m in comparison to those residing at an altitude of ~400 m.
Sulfamethoxazole is an antibacterial sulfonamide used primarily for the treatment of a wide variety of bacterial infections in combination with trimethoprim. Despite being used as prophylactic treatment for respiratory infections associated with high altitude, little information is available on the pharmacokinetic properties of sulfamethoxazole in subjects living at high altitude, especially in a Chinese population. This study was conducted to investigate the pharmacokinetics of sulfamethoxazole in healthy Chinese subjects after acute and chronic exposure to high altitude. An open-label, controlled, prospective study was conducted in healthy Chinese male volunteers. Sulfamethoxazole 1200 mg was administered orally to volunteers in 3 groups: those residing at low altitude (approximately 400 m [approximately 1300 ft]); these same volunteers after 16 hours (acute) of exposure to high altitude (approximately 3780 m [approximately 12,400 ft]); and a separate group of volunteers who had been living at high altitude (approximately 3780 m) for >or=1 year (chronic). The phases of the low-altitude and acute-exposure groups were separated by a 1-week washout period. Blood samples were collected from an indwelling venous catheter into heparinized tubes before (baseline) study drug administration and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, and 48 hours after study drug administration. Sulfamethoxazole in whole blood, plasma, and plasma water, and its metabolite, N(4)-acetyl-sulfamethoxazole, in plasma were determined by HPLC. Tolerability was determined using blood chemistry testing, continuous 12-lead ECG, and blood pressure monitoring. A total of 23 healthy Chinese male volunteers living at low altitude (race, all Han Chinese; mean [SD] age, 20.4 [1.1] years [range, 19-24 years]; weight, 64.2 [5.9] kg [range, 56.0-75.0 kg]; and height, 172.1 [4.9] cm [range, 163.0-180.0 cm]) and 21 healthy Chinese male volunteers living at high altitude (race, all Han Chinese; mean [SD] age, 21.2 [1.3] years [range, 19-24 years]; weight, 62.4 [8.2] kg [range, 50.0-75.0 kg]; and height, 171.4 [5.8] cm [range, 162.0-182.0 cm]) were enrolled in the study; 20 from each group completed the study. Concentration of sulfamethoxazole in plasma water decreased significantly after exposure to high altitude; therefore, the protein binding was significantly higher in the acute- (80.4%) and chronic-exposure (72.5%) groups compared with the low-altitude group (65.7%; both, P < 0.001). The binding of sulfamethoxazole to red blood cells was 6.0%, 6.9%, and 9.3% in the low-altitude, acute-, and chronic-exposure groups, respectively. The chronic-exposure group was 55% higher than the low-altitude group (P < 0.001). The following values were recorded in the low-altitude, acute-, and chronic-exposure groups after administration of sulfamethoxazole, respectively: mean (SD) t((1/2)), 9.30 (1.11), 10.37 (0.88), and 11.15 (1.53) hours; mean residence time (MRT(0-48)), 12.06 (0.94), 13.15 (0.67), and 13.00 (1.01) hours; elimination rate constant (k(e)), 0.076 (0.010), 0.067 (0.006), and 0.063 (0.009) hours(-1); AUC(0-48), 1202.5 (238.3), 1416.3 (202.6), and 1298.5 (256.0) micro/mL/h; and clearance (CL), 1.01 (0.22), 0.83 (0.13), and 0.92 (0.22) L/kg/h. The t((1/2)) was 11.5% and 19.9% higher in the acute- and chronic-exposure groups, respectively, compared with the low-altitude group, and 7.5% higher in the chronic-exposure group than in the acute-exposure group. MRT was 9.0% and 7.8% higher in the acute- (P < 0.05) and chronic-exposure (P < 0.001) groups, respectively, than in the low-altitude group. AUC(0-48) was 17.8% higher and CL was 17.8% lower in the acute-exposure group compared with the low-altitude group (both, P < 0.05). This study found significant changes in the disposition of sulfamethoxazole in these healthy male Chinese subjects after either acute or chronic exposure to an altitude of approximately 3780 m in comparison to those residing at an altitude of approximately 400 m.
Sulfamethoxazole is an antibacterial sulfonamide used primarily for the treatment of a wide variety of bacterial infections in combination with trimethoprim. Despite being used as prophylactic treatment for respiratory infections associated with high altitude, little information is available on the pharmacokinetic properties of sulfamethoxazole in subjects living at high altitude, especially in a Chinese population.BACKGROUNDSulfamethoxazole is an antibacterial sulfonamide used primarily for the treatment of a wide variety of bacterial infections in combination with trimethoprim. Despite being used as prophylactic treatment for respiratory infections associated with high altitude, little information is available on the pharmacokinetic properties of sulfamethoxazole in subjects living at high altitude, especially in a Chinese population.This study was conducted to investigate the pharmacokinetics of sulfamethoxazole in healthy Chinese subjects after acute and chronic exposure to high altitude.OBJECTIVEThis study was conducted to investigate the pharmacokinetics of sulfamethoxazole in healthy Chinese subjects after acute and chronic exposure to high altitude.An open-label, controlled, prospective study was conducted in healthy Chinese male volunteers. Sulfamethoxazole 1200 mg was administered orally to volunteers in 3 groups: those residing at low altitude (approximately 400 m [approximately 1300 ft]); these same volunteers after 16 hours (acute) of exposure to high altitude (approximately 3780 m [approximately 12,400 ft]); and a separate group of volunteers who had been living at high altitude (approximately 3780 m) for >or=1 year (chronic). The phases of the low-altitude and acute-exposure groups were separated by a 1-week washout period. Blood samples were collected from an indwelling venous catheter into heparinized tubes before (baseline) study drug administration and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, and 48 hours after study drug administration. Sulfamethoxazole in whole blood, plasma, and plasma water, and its metabolite, N(4)-acetyl-sulfamethoxazole, in plasma were determined by HPLC. Tolerability was determined using blood chemistry testing, continuous 12-lead ECG, and blood pressure monitoring.METHODSAn open-label, controlled, prospective study was conducted in healthy Chinese male volunteers. Sulfamethoxazole 1200 mg was administered orally to volunteers in 3 groups: those residing at low altitude (approximately 400 m [approximately 1300 ft]); these same volunteers after 16 hours (acute) of exposure to high altitude (approximately 3780 m [approximately 12,400 ft]); and a separate group of volunteers who had been living at high altitude (approximately 3780 m) for >or=1 year (chronic). The phases of the low-altitude and acute-exposure groups were separated by a 1-week washout period. Blood samples were collected from an indwelling venous catheter into heparinized tubes before (baseline) study drug administration and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, and 48 hours after study drug administration. Sulfamethoxazole in whole blood, plasma, and plasma water, and its metabolite, N(4)-acetyl-sulfamethoxazole, in plasma were determined by HPLC. Tolerability was determined using blood chemistry testing, continuous 12-lead ECG, and blood pressure monitoring.A total of 23 healthy Chinese male volunteers living at low altitude (race, all Han Chinese; mean [SD] age, 20.4 [1.1] years [range, 19-24 years]; weight, 64.2 [5.9] kg [range, 56.0-75.0 kg]; and height, 172.1 [4.9] cm [range, 163.0-180.0 cm]) and 21 healthy Chinese male volunteers living at high altitude (race, all Han Chinese; mean [SD] age, 21.2 [1.3] years [range, 19-24 years]; weight, 62.4 [8.2] kg [range, 50.0-75.0 kg]; and height, 171.4 [5.8] cm [range, 162.0-182.0 cm]) were enrolled in the study; 20 from each group completed the study. Concentration of sulfamethoxazole in plasma water decreased significantly after exposure to high altitude; therefore, the protein binding was significantly higher in the acute- (80.4%) and chronic-exposure (72.5%) groups compared with the low-altitude group (65.7%; both, P < 0.001). The binding of sulfamethoxazole to red blood cells was 6.0%, 6.9%, and 9.3% in the low-altitude, acute-, and chronic-exposure groups, respectively. The chronic-exposure group was 55% higher than the low-altitude group (P < 0.001). The following values were recorded in the low-altitude, acute-, and chronic-exposure groups after administration of sulfamethoxazole, respectively: mean (SD) t((1/2)), 9.30 (1.11), 10.37 (0.88), and 11.15 (1.53) hours; mean residence time (MRT(0-48)), 12.06 (0.94), 13.15 (0.67), and 13.00 (1.01) hours; elimination rate constant (k(e)), 0.076 (0.010), 0.067 (0.006), and 0.063 (0.009) hours(-1); AUC(0-48), 1202.5 (238.3), 1416.3 (202.6), and 1298.5 (256.0) micro/mL/h; and clearance (CL), 1.01 (0.22), 0.83 (0.13), and 0.92 (0.22) L/kg/h. The t((1/2)) was 11.5% and 19.9% higher in the acute- and chronic-exposure groups, respectively, compared with the low-altitude group, and 7.5% higher in the chronic-exposure group than in the acute-exposure group. MRT was 9.0% and 7.8% higher in the acute- (P < 0.05) and chronic-exposure (P < 0.001) groups, respectively, than in the low-altitude group. AUC(0-48) was 17.8% higher and CL was 17.8% lower in the acute-exposure group compared with the low-altitude group (both, P < 0.05).RESULTSA total of 23 healthy Chinese male volunteers living at low altitude (race, all Han Chinese; mean [SD] age, 20.4 [1.1] years [range, 19-24 years]; weight, 64.2 [5.9] kg [range, 56.0-75.0 kg]; and height, 172.1 [4.9] cm [range, 163.0-180.0 cm]) and 21 healthy Chinese male volunteers living at high altitude (race, all Han Chinese; mean [SD] age, 21.2 [1.3] years [range, 19-24 years]; weight, 62.4 [8.2] kg [range, 50.0-75.0 kg]; and height, 171.4 [5.8] cm [range, 162.0-182.0 cm]) were enrolled in the study; 20 from each group completed the study. Concentration of sulfamethoxazole in plasma water decreased significantly after exposure to high altitude; therefore, the protein binding was significantly higher in the acute- (80.4%) and chronic-exposure (72.5%) groups compared with the low-altitude group (65.7%; both, P < 0.001). The binding of sulfamethoxazole to red blood cells was 6.0%, 6.9%, and 9.3% in the low-altitude, acute-, and chronic-exposure groups, respectively. The chronic-exposure group was 55% higher than the low-altitude group (P < 0.001). The following values were recorded in the low-altitude, acute-, and chronic-exposure groups after administration of sulfamethoxazole, respectively: mean (SD) t((1/2)), 9.30 (1.11), 10.37 (0.88), and 11.15 (1.53) hours; mean residence time (MRT(0-48)), 12.06 (0.94), 13.15 (0.67), and 13.00 (1.01) hours; elimination rate constant (k(e)), 0.076 (0.010), 0.067 (0.006), and 0.063 (0.009) hours(-1); AUC(0-48), 1202.5 (238.3), 1416.3 (202.6), and 1298.5 (256.0) micro/mL/h; and clearance (CL), 1.01 (0.22), 0.83 (0.13), and 0.92 (0.22) L/kg/h. The t((1/2)) was 11.5% and 19.9% higher in the acute- and chronic-exposure groups, respectively, compared with the low-altitude group, and 7.5% higher in the chronic-exposure group than in the acute-exposure group. MRT was 9.0% and 7.8% higher in the acute- (P < 0.05) and chronic-exposure (P < 0.001) groups, respectively, than in the low-altitude group. AUC(0-48) was 17.8% higher and CL was 17.8% lower in the acute-exposure group compared with the low-altitude group (both, P < 0.05).This study found significant changes in the disposition of sulfamethoxazole in these healthy male Chinese subjects after either acute or chronic exposure to an altitude of approximately 3780 m in comparison to those residing at an altitude of approximately 400 m.CONCLUSIONThis study found significant changes in the disposition of sulfamethoxazole in these healthy male Chinese subjects after either acute or chronic exposure to an altitude of approximately 3780 m in comparison to those residing at an altitude of approximately 400 m.
Abstract Background: Sulfamethoxazole is an antibacterial sulfonamide used primarily for the treatment of a wide variety of bacterial infections in combination with trimethoprim. Despite being used as prophylactic treatment for respiratory infections associated with high altitude, little information is available on the pharmacokinetic properties of sulfamethoxazole in subjects living at high altitude, especially in a Chinese population. Objective: This study was conducted to investigate the pharmacokinetics of sulfamethoxazole in healthy Chinese subjects after acute and chronic exposure to high altitude. Methods: An open-label, controlled, prospective study was conducted in healthy Chinese male volunteers. Sulfamethoxazole 1200 mg was administered orally to volunteers in 3 groups: those residing at low altitude (~400 m [~1300 ft]); these same volunteers after 16 hours (acute) of exposure to high altitude (~3780 m [~12,400 ft]); and a separate group of volunteers who had been living at high altitude (~3780 m) for ≥1 year (chronic). The phases of the low-altitude and acute-exposure groups were separated by a 1-week washout period. Blood samples were collected from an indwelling venous catheter into heparinized tubes before (baseline) study drug administration and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, and 48 hours after study drug administration. Sulfamethoxazole in whole blood, plasma, and plasma water, and its metabolite, N4 -acetyl-sulfamethoxazole, in plasma were determined by HPLC. Tolerability was determined using blood chemistry testing, continuous 12-lead ECG, and blood pressure monitoring. Results: A total of 23 healthy Chinese male volunteers living at low altitude (race, all Han Chinese; mean [SD] age, 20.4 [1.1] years [range, 19–24 years]; weight, 64.2 [5.9] kg [range, 56.0–75.0 kg]; and height, 172.1 [4.9] cm [range, 163.0–180.0 cm]) and 21 healthy Chinese male volunteers living at high altitude (race, all Han Chinese; mean [SD] age, 21.2 [1.3] years [range, 19–24 years]; weight, 62.4 [8.2] kg [range, 50.0–75.0 kg]; and height, 171.4 [5.8] cm [range, 162.0–182.0 cm]) were enrolled in the study; 20 from each group completed the study. Concentration of sulfamethoxazole in plasma water decreased significantly after exposure to high altitude; therefore, the protein binding was significantly higher in the acute- (80.4%) and chronic-exposure (72.5%) groups compared with the low-altitude group (65.7%; both, P < 0.001). The binding of sulfamethoxazole to red blood cells was 6.0%, 6.9%, and 9.3% in the low-altitude, acute-, and chronic-exposure groups, respectively. The chronic-exposure group was 55% higher than the low-altitude group ( P < 0.001). The following values were recorded in the low-altitude, acute-, and chronic-exposure groups after administration of sulfamethoxazole, respectively: mean (SD) t½ , 9.30 (1.11), 10.37 (0.88), and 11.15 (1.53) hours; mean residence time (MRT0–48 ), 12.06 (0.94), 13.15 (0.67), and 13.00 (1.01) hours; elimination rate constant (ke ), 0.076 (0.010), 0.067 (0.006), and 0.063 (0.009) hours−1 ; AUC0–48 , 1202.5 (238.3), 1416.3 (202.6), and 1298.5 (256.0) μ/mL/h; and clearance (CL), 1.01 (0.22), 0.83 (0.13), and 0.92 (0.22) L/kg/h. The t½ was 11.5% and 19.9% higher in the acute- and chronic-exposure groups, respectively, compared with the low-altitude group, and 7.5% higher in the chronic-exposure group than in the acute-exposure group. MRT was 9.0% and 7.8% higher in the acute- ( P < 0.05) and chronic-exposure ( P < 0.001) groups, respectively, than in the low-altitude group. AUC0–48 was 17.8% higher and CL was 17.8% lower in the acute-exposure group compared with the low-altitude group (both, P < 0.05). Conclusion: This study found significant changes in the disposition of sulfamethoxazole in these healthy male Chinese subjects after either acute or chronic exposure to an altitude of ~3780 m in comparison to those residing at an altitude of ~400 m.
Background_ Sulfamethoxazole is an antibacterial sulfonamide used primarily for the treatment of a wide variety of bacterial infections in combination with trimethoprim. Despite being used as prophylactic treatment for respiratory infections associated with high altitude, little information is available on the pharmacokinetic properties of sulfamethoxazole in subjects living at high altitude, especially in a Chinese population. Objective_ This study was conducted to investigate the pharmacokinetics of sulfamethoxazole in healthy Chinese subjects after acute and chronic exposure to high altitude. Methods_ An open-label, controlled, prospective study was conducted in healthy Chinese male volunteers. Sulfamethoxazole 1200 mg was administered orally to volunteers in 3 groups: those residing at low altitude (~400 m [~1300 ft]); these same volunteers after 16 hours (acute) of exposure to high altitude (~3780 m [~12,400 ft]); and a separate group of volunteers who had been living at high altitude (~3780 m) for ≥1 year (chronic). The phases of the low-altitude and acute-exposure groups were separated by a 1-week washout period. Blood samples were collected from an indwelling venous catheter into heparinized tubes before (baseline) study drug administration and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, and 48 hours after study drug administration. Sulfamethoxazole in whole blood, plasma, and plasma water, and its metabolite, N4 -acetyl-sulfamethoxazole, in plasma were determined by HPLC. Tolerability was determined using blood chemistry testing, continuous 12-lead ECG, and blood pressure monitoring. Results_ A total of 23 healthy Chinese male volunteers living at low altitude (race, all Han Chinese; mean [SD] age, 20.4 [1.1] years [range, 19-24 years]; weight, 64.2 [5.9] kg [range, 56.0-75.0 kg]; and height, 172.1 [4.9] cm [range, 163.0-180.0 cm]) and 21 healthy Chinese male volunteers living at high altitude (race, all Han Chinese; mean [SD] age, 21.2 [1.3] years [range, 19-24 years]; weight, 62.4 [8.2] kg [range, 50.0-75.0 kg]; and height, 171.4 [5.8] cm [range, 162.0-182.0 cm]) were enrolled in the study; 20 from each group completed the study. Concentration of sulfamethoxazole in plasma water decreased significantly after exposure to high altitude; therefore, the protein binding was significantly higher in the acute- (80.4%) and chronic-exposure (72.5%) groups compared with the low-altitude group (65.7%; both, P < 0.001). The binding of sulfamethoxazole to red blood cells was 6.0%, 6.9%, and 9.3% in the low-altitude, acute-, and chronic-exposure groups, respectively. The chronic-exposure group was 55% higher than the low-altitude group (P < 0.001). The following values were recorded in the low-altitude, acute-, and chronic-exposure groups after administration of sulfamethoxazole, respectively: mean (SD) t½, 9.30 (1.11), 10.37 (0.88), and 11.15 (1.53) hours; mean residence time (MRT0-48), 12.06 (0.94), 13.15 (0.67), and 13.00 (1.01) hours; elimination rate constant (ke), 0.076 (0.010), 0.067 (0.006), and 0.063 (0.009) hours-1 ; AUC0-48, 1202.5 (238.3), 1416.3 (202.6), and 1298.5 (256.0) μ/mL/h; and clearance (CL), 1.01 (0.22), 0.83 (0.13), and 0.92 (0.22) L/kg/h. The t½ was 11.5% and 19.9% higher in the acute- and chronic-exposure groups, respectively, compared with the low-altitude group, and 7.5% higher in the chronic-exposure group than in the acute-exposure group. MRT was 9.0% and 7.8% higher in the acute- (P < 0.05) and chronic-exposure (P < 0.001) groups, respectively, than in the low-altitude group. AUC0-48 was 17.8% higher and CL was 17.8% lower in the acute-exposure group compared with the low-altitude group (both, P < 0.05). Conclusion_ This study found significant changes in the disposition of sulfamethoxazole in these healthy male Chinese subjects after either acute or chronic exposure to an altitude of ~3780 m in comparison to those residing at an altitude of ~400 m.
Author Li, Zhan-Quan
Gao, Fen
Ge, Ri-Li
Li, Xiang-Yang
Guan, Wei
Feng, Wei-Li
Author_xml – sequence: 1
  givenname: Xiang-Yang
  surname: Li
  fullname: Li, Xiang-Yang
  organization: Department of Pharmacology, College of Life Science, Shenyang Pharmaceutical University, Shenyang, China
– sequence: 2
  givenname: Fen
  surname: Gao
  fullname: Gao, Fen
  organization: Department of Respiration, First Affiliated Hospital, Qinghai University, Xining, China
– sequence: 3
  givenname: Zhan-Quan
  surname: Li
  fullname: Li, Zhan-Quan
  organization: Department of Respiration, First Affiliated Hospital, Qinghai University, Xining, China
– sequence: 4
  givenname: Wei
  surname: Guan
  fullname: Guan, Wei
  organization: Department of Respiration, First Affiliated Hospital, Qinghai University, Xining, China
– sequence: 5
  givenname: Wei-Li
  surname: Feng
  fullname: Feng, Wei-Li
  organization: Research Center for High Altitude Medicine, Qinghai University Medical College, Xining, China
– sequence: 6
  givenname: Ri-Li
  surname: Ge
  fullname: Ge, Ri-Li
  email: geriligao@hotmail.com
  organization: Research Center for High Altitude Medicine, Qinghai University Medical College, Xining, China
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22280246$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/20110016$$D View this record in MEDLINE/PubMed
BookMark eNqNkl1rFDEUhgep2A_9CxoQ8aa7JpP9SASVZfELCl7YC-_CmcyZTraZZJpk1q5_2L9hhq0tFoReBcLzPjmcvMfFgfMOi-IFo1NG2eLNZqqtcanFANOSUjllbEqZfFQcMbGUE8ZmPw6KI8pmclJKJg6L4xg3lFIu5-WT4rCkjNHsOSp-r33XQzDRO-Ibko2kbyF0oP2lcZiMjuN9HGwDHabWX8Mvb5EYRzrIp24zFZFsvR1cQgyRQCLW_yRgk0lDjQRcTUAPCQle9z4OAUnypDUX7R2zzcEh5meqDeoUiTVb4y6yPXhnNFi7G7X_ZN6SVR65RzexUKE9Jdq7FLy1WJ-SPvjYZ5PZIomZ3j0tHjdgIz67OU-K808fz9dfJmffPn9dr84mes5lmohqOaureoFUlBz4Upa4aBZC1wwAmpo2gldQ8ZIKOqecSZDLuWjoXMuZ5nXDT4rXe20e4GrAmFRnokZrwaEfolpyLhYLIUQmX94jN34ILs-mGOWczUUpZKae31BD1WGt-mA6CDv19wMz8OoGgJj31ARw2sQ7riwFLWcjt9xzOm8mBmxuEUbVWCm1UbeVUmOlFGMqVyon391LapMgmXHbYOwD8qt9HvPatwaDitqg01ibkH9I1d48wPH-nmPkxmJc4g7j3eZULBVV38fij72nktIZlTwLPvxf8KAR_gCS-x4p
CitedBy_id crossref_primary_10_1007_s13318_012_0090_0
crossref_primary_10_1016_j_toxlet_2020_05_006
crossref_primary_10_3389_fphar_2021_692349
crossref_primary_10_3390_ph15101303
crossref_primary_10_1016_j_envpol_2020_116408
crossref_primary_10_1111_jphp_12098
crossref_primary_10_1124_dmd_121_000681
crossref_primary_10_2174_1389200220666190405171303
crossref_primary_10_2139_ssrn_3916104
crossref_primary_10_1089_ham_2017_0121
crossref_primary_10_1016_j_etap_2017_03_019
crossref_primary_10_1007_s40262_014_0209_3
crossref_primary_10_2174_1389200224666221228115526
crossref_primary_10_2174_1389200219666181019145159
crossref_primary_10_1007_s00253_011_3742_0
crossref_primary_10_2174_1389200223666220128141038
crossref_primary_10_1002_jcph_2376
crossref_primary_10_1039_C7RA03025H
crossref_primary_10_1080_17425255_2017_1360867
crossref_primary_10_1089_ham_2014_1026
crossref_primary_10_1159_000358128
crossref_primary_10_1016_j_dmd_2024_100026
crossref_primary_10_2478_fzm_2023_0012
crossref_primary_10_1038_aps_2013_146
crossref_primary_10_1016_j_biopha_2017_02_092
Cites_doi 10.1007/s00228-004-0886-1
10.1089/152702900320667
10.1016/j.emc.2004.02.001
10.5414/CPP41200
10.5414/CPP42314
10.1248/cpb.32.2414
10.1067/mcp.2002.121789
10.1161/01.CIR.61.3.463
10.1152/jappl.1988.64.4.1309
10.5414/CPP43085
10.1152/jappl.2001.90.2.528
10.1016/0006-2952(93)90280-A
10.1055/s-2007-1021020
10.1001/archinte.163.4.402
10.1002/j.1552-4604.1998.tb05791.x
10.1378/chest.07-1417
10.1172/JCI105452
10.1358/mf.1998.20.2.485649
10.1007/BF00192744
10.1002/j.1552-4604.1996.tb04225.x
10.2165/00003088-198611050-00003
ContentType Journal Article
Copyright 2009 Excerpta Medica Inc.
Excerpta Medica Inc.
2015 INIST-CNRS
Copyright 2009 Excerpta Medica Inc. All rights reserved.
Copyright_xml – notice: 2009 Excerpta Medica Inc.
– notice: Excerpta Medica Inc.
– notice: 2015 INIST-CNRS
– notice: Copyright 2009 Excerpta Medica Inc. All rights reserved.
DBID AAYXX
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7RV
7X7
7XB
88C
88E
8AO
8FI
8FJ
8FK
8G5
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
GUQSH
K9.
KB0
M0S
M0T
M1P
M2O
M7N
MBDVC
NAPCQ
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
Q9U
7X8
DOI 10.1016/j.clinthera.2009.11.019
DatabaseName CrossRef
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Nursing & Allied Health Database
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Healthcare Administration Database (Alumni)
Medical Database (Alumni Edition)
ProQuest Pharma Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
Research Library (Alumni)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
ProQuest Research Library
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Database (Alumni Edition)
Health & Medical Collection (Alumni)
Healthcare Administration Database
Medical Database
Research Library
Algology Mycology and Protozoology Abstracts (Microbiology C)
Research Library (Corporate)
Nursing & Allied Health Premium
ProQuest Central Premium
ProQuest One Academic
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Research Library Prep
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
Research Library (Alumni Edition)
ProQuest Pharma Collection
ProQuest Central China
ProQuest Central
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Algology Mycology and Protozoology Abstracts (Microbiology C)
Health & Medical Research Collection
ProQuest Research Library
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Central Basic
ProQuest One Academic Eastern Edition
ProQuest Health Management
ProQuest Nursing & Allied Health Source
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
Nursing & Allied Health Premium
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest Health Management (Alumni Edition)
ProQuest Nursing & Allied Health Source (Alumni)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
MEDLINE
MEDLINE - Academic

Research Library Prep

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: http://www.proquest.com/pqcentral?accountid=15518
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Pharmacy, Therapeutics, & Pharmacology
EISSN 1879-114X
EndPage 2754
ExternalDocumentID 2734241651
20110016
22280246
10_1016_j_clinthera_2009_11_019
S0149291809004093
1_s2_0_S0149291809004093
Genre Comparative Study
Clinical Trial
Research Support, Non-U.S. Gov't
Journal Article
GeographicLocations Asia
China
GeographicLocations_xml – name: China
GroupedDBID ---
--K
--M
.1-
.FO
.GJ
.~1
0R~
123
1B1
1P~
1~.
1~5
29B
4.4
457
4G.
53G
5RE
5VS
6J9
6PF
7-5
71M
7RV
7X7
88E
8AO
8FI
8FJ
8G5
8P~
AABNK
AAEDT
AAEDW
AAIKJ
AAKOC
AALRI
AAOAW
AAQFI
AAQQT
AAQXK
AATTM
AAWTL
AAXKI
AAXUO
AAYWO
ABBQC
ABFNM
ABFRF
ABJNI
ABMAC
ABMZM
ABUWG
ABWVN
ABXDB
ABZDS
ACDAQ
ACIEU
ACPRK
ACRLP
ACRPL
ACVFH
ADBBV
ADCNI
ADEZE
ADFRT
ADMUD
ADNMO
ADVLN
AEBSH
AEFWE
AEIPS
AEKER
AENEX
AEUPX
AEVXI
AFFNX
AFJKZ
AFKRA
AFPUW
AFRAH
AFRHN
AFTJW
AFXIZ
AGCQF
AGHFR
AGQPQ
AGUBO
AGYEJ
AHMBA
AIEXJ
AIGII
AIIUN
AIKHN
AITUG
AJRQY
AJUYK
AKBMS
AKRWK
AKYEP
ALCLG
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
ANKPU
ANZVX
APXCP
AQUVI
ASPBG
AVWKF
AXJTR
AZFZN
AZQEC
BENPR
BKEYQ
BKOJK
BLXMC
BNPGV
BPHCQ
BVXVI
CCPQU
CS3
DU5
DWQXO
EBS
EFJIC
EFKBS
EJD
EMOBN
EO8
EO9
EP2
EP3
EX3
F5P
FDB
FEDTE
FGOYB
FIRID
FNPLU
FYGXN
FYUFA
G-Q
GBLVA
GNUQQ
GUQSH
HMCUK
HVGLF
HZ~
H~9
IHE
J1W
KOM
M0T
M1P
M2O
M41
MO0
N9A
NAPCQ
O-L
O9-
OAUVE
OD~
OGGZJ
OO0
OZT
P-8
P-9
PC.
PHGZM
PHGZT
PJZUB
PPXIY
PQQKQ
PROAC
PSQYO
PUEGO
Q38
R2-
ROL
RPZ
SCC
SDF
SDG
SEL
SES
SEW
SPCBC
SSH
SSP
SSZ
SV3
T5K
UHS
UKHRP
WH7
WOW
XOL
Z5R
ZGI
ZXP
~G-
0SF
3V.
AACTN
AAYOK
AFCTW
AFKWA
AJOXV
ALIPV
AMFUW
NCXOZ
RIG
AAIAV
AATCM
ABLVK
ABYKQ
AJBFU
EFLBG
LCYCR
AAYXX
ACLOT
CITATION
~HD
AGRNS
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
7XB
8FK
K9.
M7N
MBDVC
PKEHL
PQEST
PQUKI
PRINS
Q9U
7X8
ID FETCH-LOGICAL-c539t-8b74dbd6e0823a3792e6f68cd1aaafd0f83bab3208050319a9758f05c94c3df3
IEDL.DBID .~1
ISSN 0149-2918
1879-114X
IngestDate Wed Oct 01 17:14:27 EDT 2025
Wed Aug 13 09:19:33 EDT 2025
Mon Jul 21 05:38:39 EDT 2025
Mon Jul 21 09:11:39 EDT 2025
Thu Apr 24 22:56:28 EDT 2025
Wed Oct 01 04:57:58 EDT 2025
Fri Feb 23 02:23:25 EST 2024
Sun Feb 23 10:18:56 EST 2025
Tue Aug 26 16:34:17 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 11
Keywords pharmacokinetics
high altitude
sulfamethoxazole
healthy volunteers
Human
High altitude
Healthy subject
Acute
Volunteer
Environmental factor
Male
Exposure
Prospective
Chronic
Sulfamethoxazole
Sulfonamides
Chinese
Antiinfectious
Antibacterial agent
Pharmacokinetics
Comparative study
Altitude
Language English
License https://www.elsevier.com/tdm/userlicense/1.0
CC BY 4.0
Copyright 2009 Excerpta Medica Inc. All rights reserved.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c539t-8b74dbd6e0823a3792e6f68cd1aaafd0f83bab3208050319a9758f05c94c3df3
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-News-1
content type line 14
ObjectType-Feature-3
ObjectType-Feature-1
content type line 23
PMID 20110016
PQID 1033158289
PQPubID 1226358
PageCount 11
ParticipantIDs proquest_miscellaneous_733866888
proquest_journals_1033158289
pubmed_primary_20110016
pascalfrancis_primary_22280246
crossref_primary_10_1016_j_clinthera_2009_11_019
crossref_citationtrail_10_1016_j_clinthera_2009_11_019
elsevier_sciencedirect_doi_10_1016_j_clinthera_2009_11_019
elsevier_clinicalkeyesjournals_1_s2_0_S0149291809004093
elsevier_clinicalkey_doi_10_1016_j_clinthera_2009_11_019
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2009-11-01
PublicationDateYYYYMMDD 2009-11-01
PublicationDate_xml – month: 11
  year: 2009
  text: 2009-11-01
  day: 01
PublicationDecade 2000
PublicationPlace Bridgewater, NJ
PublicationPlace_xml – name: Bridgewater, NJ
– name: United States
– name: Bridgewater
PublicationTitle Clinical therapeutics
PublicationTitleAlternate Clin Ther
PublicationYear 2009
Publisher EM Inc USA
Elsevier
Elsevier Limited
Publisher_xml – name: EM Inc USA
– name: Elsevier
– name: Elsevier Limited
References Masters, O’Bryan, Zurlo (bib16) 2003; 163
Jung, Hwang, Lee (bib19) 2001; 22
Jürgens, Christensen, Brøsen (bib33) 2002; 71
Rowell, Blackmon, Kenny, Escourrou (bib5) 1984; 247
Arancibia, Paulos, Chávez, Ritschel (bib12) 2003; 41
Aslam, Khan (bib9) 1996; 46
Cribb, Nakamura, Grant (bib32) 1993; 45
Sutton, Reeves, Wagner (bib3) 1988; 64
Bergan, Ortengren, Westerlund (bib17) 1986; 11
Imoberdorf, Garlick, McNurlan (bib27) 2001; 90
Chen, Zheng, Sun (bib21) 2002; 7
Benet, Kroetz, Sheiner (bib25) 1990
Ritschel, Paulos, Arancibia (bib11) 1996; 18
Zhao, Shi, Zhang (bib18) 2001; 17
Gallagher, Hackett, Gallagher, Hackett (bib7) 2004; 22
Streit, Göggelmann, Dehnert (bib34) 2005; 61
Duplain, Sartori, Scherrer (bib1) 2007; 3
Yu (bib23) 2007
Ritschel (bib22) 1992
Ha, Zhu, Zhang (bib20) 2002; 25
(bib24) 2005
Arancibia, Nella Gai, Paulos (bib30) 2004; 42
Mairbäurl (bib2) 1994; 15
Ritschel, Paulos, Arancibia (bib14) 1998; 20
Arancibia, Gai, Chávez (bib29) 2005; 43
Heistad, Abboud, Dickinson (bib4) 1980; 61
Ritschel, Paulos, Arancibia (bib13) 1998; 38
Ritschel, Paulos, Arancibia (bib10) 1996; 36
Maruyama, Harada, Nishigori, Iwatsuru (bib28) 1984; 32
Wolff (bib6) 2000; 1
Kamimori, Eddington, Hoyt (bib15) 1995; 48
Surks (bib26) 1966; 45
Reilly, Woster, Svensson (bib31) 1999; 288
Luks, Swenson (bib8) 2008; 133
Duplain (10.1016/j.clinthera.2009.11.019_bib1) 2007; 3
Wolff (10.1016/j.clinthera.2009.11.019_bib6) 2000; 1
Gallagher (10.1016/j.clinthera.2009.11.019_bib7_1) 2004; 22
Arancibia (10.1016/j.clinthera.2009.11.019_bib12) 2003; 41
Surks (10.1016/j.clinthera.2009.11.019_bib26) 1966; 45
Mairbäurl (10.1016/j.clinthera.2009.11.019_bib2) 1994; 15
Ritschel (10.1016/j.clinthera.2009.11.019_bib11) 1996; 18
Jung (10.1016/j.clinthera.2009.11.019_bib19) 2001; 22
Chen (10.1016/j.clinthera.2009.11.019_bib21) 2002; 7
Bergan (10.1016/j.clinthera.2009.11.019_bib17) 1986; 11
Yu (10.1016/j.clinthera.2009.11.019_bib23) 2007
Zhao (10.1016/j.clinthera.2009.11.019_bib18) 2001; 17
Luks (10.1016/j.clinthera.2009.11.019_bib8) 2008; 133
Ritschel (10.1016/j.clinthera.2009.11.019_bib10) 1996; 36
Streit (10.1016/j.clinthera.2009.11.019_bib34) 2005; 61
Sutton (10.1016/j.clinthera.2009.11.019_bib3) 1988; 64
Reilly (10.1016/j.clinthera.2009.11.019_bib31) 1999; 288
Cribb (10.1016/j.clinthera.2009.11.019_bib32) 1993; 45
Jürgens (10.1016/j.clinthera.2009.11.019_bib33) 2002; 71
Arancibia (10.1016/j.clinthera.2009.11.019_bib29) 2005; 43
Ritschel (10.1016/j.clinthera.2009.11.019_bib14) 1998; 20
Imoberdorf (10.1016/j.clinthera.2009.11.019_bib27) 2001; 90
Aslam (10.1016/j.clinthera.2009.11.019_bib9) 1996; 46
Benet (10.1016/j.clinthera.2009.11.019_bib25) 1990
Rowell (10.1016/j.clinthera.2009.11.019_bib5) 1984; 247
(10.1016/j.clinthera.2009.11.019_bib24) 2005
Gallagher (10.1016/j.clinthera.2009.11.019_bib7_2) 2004; 22
Ha (10.1016/j.clinthera.2009.11.019_bib20) 2002; 25
Maruyama (10.1016/j.clinthera.2009.11.019_bib28) 1984; 32
Kamimori (10.1016/j.clinthera.2009.11.019_bib15) 1995; 48
Masters (10.1016/j.clinthera.2009.11.019_bib16) 2003; 163
Ritschel (10.1016/j.clinthera.2009.11.019_bib13) 1998; 38
Ritschel (10.1016/j.clinthera.2009.11.019_bib22) 1992
Heistad (10.1016/j.clinthera.2009.11.019_bib4) 1980; 61
Arancibia (10.1016/j.clinthera.2009.11.019_bib30) 2004; 42
References_xml – volume: 15
  start-page: 51
  year: 1994
  end-page: 63
  ident: bib2
  article-title: Red blood cell function in hypoxia at altitude and exercise
  publication-title: Int J Sports Med.
– volume: 71
  start-page: 214
  year: 2002
  end-page: 220
  ident: bib33
  article-title: Acute hypoxia and cytochrome P450-mediated hepatic drug metabolism in humans
  publication-title: Clin Pharmacol Ther.
– volume: 46
  start-page: 90
  year: 1996
  end-page: 92
  ident: bib9
  article-title: The role of drugs in high altitude disorders
  publication-title: J Pak Med Assoc.
– volume: 18
  start-page: 49
  year: 1996
  end-page: 53
  ident: bib11
  article-title: Urinary excretion of meperidine and normeperedine in man upon acute and chronic exposure to high altitude
  publication-title: Methods Find Exp Clin Pharmacol.
– year: 2007
  ident: bib23
  publication-title: SPSS and Statistic Analysis.
– volume: 61
  start-page: 463
  year: 1980
  end-page: 470
  ident: bib4
  article-title: Richards lecture: Circulatory adjustments to hypoxia
  publication-title: Circulation
– volume: 22
  start-page: 329
  year: 2004
  end-page: 355
  ident: bib7
  article-title: High altitude illness
  publication-title: Emerg Med Clin North Am.
– volume: 36
  start-page: 610
  year: 1996
  end-page: 616
  ident: bib10
  article-title: Pharmacokinetics of meperidine in healthy volunteers after short- and long-term exposure to high altitude
  publication-title: J Clin Pharmacol.
– volume: 25
  start-page: 527
  year: 2002
  end-page: 530
  ident: bib20
  article-title: The effect of rhodiola and acetazolamide on the sleep architecture and blood oxygen saturation in men living at high altitude
  publication-title: Zhonghua Jie He He Hu Xi Za Zhi
– volume: 133
  start-page: 744
  year: 2008
  end-page: 755
  ident: bib8
  article-title: Medication and dosage considerations in the prophylaxis and treatment of high-altitude illness
  publication-title: Chest.
– volume: 20
  start-page: 133
  year: 1998
  end-page: 137
  ident: bib14
  article-title: Urinary excretion of acetazolamide in healthy volunteers after short- and long-term exposure to high altitude
  publication-title: Methods Find Exp Clin Pharmacol.
– volume: 48
  start-page: 167
  year: 1995
  end-page: 170
  ident: bib15
  article-title: Effects of altitude (4300 m) on the pharmacokinetics of caffeine and cardio-green in humans
  publication-title: Eur J Clin Pharmacol.
– volume: 42
  start-page: 314
  year: 2004
  end-page: 320
  ident: bib30
  article-title: Effects of high altitude exposure on the pharmacokinetics of furosemide in healthy volunteers [published correction appears in
  publication-title: Int J Clin Pharmacol Ther.
– volume: 288
  start-page: 951
  year: 1999
  end-page: 959
  ident: bib31
  article-title: Methemoglobin formation by hydroxylamine metabolites of sulfamethoxazole and dapsone: Implications for differences in adverse drug reactions
  publication-title: J Pharmacol Exp Ther.
– volume: 247
  start-page: H251
  year: 1984
  end-page: H258
  ident: bib5
  article-title: Splanchnic vasomotor and metabolic adjustments to hypoxia and exercise in humans
  publication-title: AmJ Physiol.
– volume: 45
  start-page: 1277
  year: 1993
  end-page: 1282
  ident: bib32
  article-title: Role of polymorphic and monomorphic human arylamine N-acetyltransferases in determining sulfamethoxazole metabolism
  publication-title: Biochem Pharmacol.
– volume: 43
  start-page: 85
  year: 2005
  end-page: 91
  ident: bib29
  article-title: Pharmacokinetics of prednisolone in man during acute and chronic exposure to high altitude
  publication-title: Int J Clin Pharmacol Ther.
– volume: 45
  start-page: 1442
  year: 1966
  end-page: 1451
  ident: bib26
  article-title: Metabolism of human serum albumin in man during acute exposure to high altitude (14,100 feet)
  publication-title: J Clin Invest.
– volume: 1
  start-page: 33
  year: 2000
  end-page: 38
  ident: bib6
  article-title: Cerebral blood flow and oxygen delivery at high altitude
  publication-title: High Alt Med Biol.
– start-page: 153
  year: 1992
  ident: bib22
  article-title: Binding of drugs to biological material
  publication-title: Handbook of Basic Pharmacokinetics-Including Clinical Applications
– year: 1990
  ident: bib25
  article-title: Pharmacokinetics: The dynamics of drug absorption, distribution, and elimination
  publication-title: Goodman and Gilman's The Pharmacological Basis of Therapeutics
– volume: 64
  start-page: 1309
  year: 1988
  end-page: 1321
  ident: bib3
  article-title: Operation Everest II: Oxygen transport during exercise at extreme simulated altitude
  publication-title: J Appl Physiol.
– volume: 11
  start-page: 372
  year: 1986
  end-page: 386
  ident: bib17
  article-title: Clinical pharmacokinetics of cotrimazine
  publication-title: Clin Pharmacokinet.
– volume: 3
  start-page: 1766
  year: 2007
  end-page: 1769
  ident: bib1
  article-title: High-altitude related illness [in French]
  publication-title: Rev Med Suisse.
– volume: 38
  start-page: 533
  year: 1998
  end-page: 539
  ident: bib13
  article-title: Pharmacokinetics of acetazolamide in healthy volunteers after short- and long-term exposure to high altitude
  publication-title: J Clin Pharmacol.
– volume: 32
  start-page: 2414
  year: 1984
  end-page: 2420
  ident: bib28
  article-title: Classification of drugs on the basis of bilirubin-displacing effect on human serum albumin
  publication-title: Chem Pharm Bull.
– year: 2005
  ident: bib24
  publication-title: Technical guidelines of chemical drugs in clinical pharmacokinetics studies
– volume: 17
  start-page: 348
  year: 2001
  end-page: 351
  ident: bib18
  article-title: Pharmacokinetic study of sulfamethoxazole and N4-acetylsulfamethoxazol
  publication-title: Chin J Clin Pharmacol.
– volume: 90
  start-page: 528
  year: 2001
  end-page: 537
  ident: bib27
  article-title: Enhanced synthesis of albumin and fibrinogen at high altitude
  publication-title: J Appl Physiol.
– volume: 61
  start-page: 39
  year: 2005
  end-page: 46
  ident: bib34
  article-title: Cytochrome P450 enzymemediated drug metabolism at exposure to acute hypoxia (corresponding to an altitude of 4,500 m)
  publication-title: Eur J Clin Pharmacol.
– volume: 22
  start-page: 1765
  year: 2001
  end-page: 1771
  ident: bib19
  article-title: Comparative consistency between obesity determination standards using body mass index and ideal body weight
  publication-title: J Korean Acad Fam Med.
– volume: 163
  start-page: 402
  year: 2003
  end-page: 410
  ident: bib16
  article-title: Trimethoprim-sulfamethoxazole revisited
  publication-title: Arch Intern Med.
– volume: 7
  start-page: 562
  year: 2002
  end-page: 564
  ident: bib21
  article-title: Functions of the DAS software for pharmacologycal calculation
  publication-title: Chin J Clin Pharmacol Ther.
– volume: 41
  start-page: 200
  year: 2003
  end-page: 206
  ident: bib12
  article-title: Pharmacokinetics of lithium in healthy volunteers after exposure to high altitude
  publication-title: Int J Clin Pharmacol Ther.
– volume: 3
  start-page: 1766
  year: 2007
  ident: 10.1016/j.clinthera.2009.11.019_bib1
  article-title: High-altitude related illness [in French]
  publication-title: Rev Med Suisse.
– volume: 61
  start-page: 39
  year: 2005
  ident: 10.1016/j.clinthera.2009.11.019_bib34
  article-title: Cytochrome P450 enzymemediated drug metabolism at exposure to acute hypoxia (corresponding to an altitude of 4,500 m)
  publication-title: Eur J Clin Pharmacol.
  doi: 10.1007/s00228-004-0886-1
– volume: 1
  start-page: 33
  year: 2000
  ident: 10.1016/j.clinthera.2009.11.019_bib6
  article-title: Cerebral blood flow and oxygen delivery at high altitude
  publication-title: High Alt Med Biol.
  doi: 10.1089/152702900320667
– volume: 22
  start-page: 329
  year: 2004
  ident: 10.1016/j.clinthera.2009.11.019_bib7_1
  article-title: High altitude illness
  publication-title: Emerg Med Clin North Am.
  doi: 10.1016/j.emc.2004.02.001
– volume: 41
  start-page: 200
  year: 2003
  ident: 10.1016/j.clinthera.2009.11.019_bib12
  article-title: Pharmacokinetics of lithium in healthy volunteers after exposure to high altitude
  publication-title: Int J Clin Pharmacol Ther.
  doi: 10.5414/CPP41200
– volume: 42
  start-page: 314
  year: 2004
  ident: 10.1016/j.clinthera.2009.11.019_bib30
  article-title: Effects of high altitude exposure on the pharmacokinetics of furosemide in healthy volunteers [published correction appears in Int J Clin Pharmacol Ther. 2004;42:526]
  publication-title: Int J Clin Pharmacol Ther.
  doi: 10.5414/CPP42314
– volume: 288
  start-page: 951
  year: 1999
  ident: 10.1016/j.clinthera.2009.11.019_bib31
  article-title: Methemoglobin formation by hydroxylamine metabolites of sulfamethoxazole and dapsone: Implications for differences in adverse drug reactions
  publication-title: J Pharmacol Exp Ther.
– volume: 32
  start-page: 2414
  year: 1984
  ident: 10.1016/j.clinthera.2009.11.019_bib28
  article-title: Classification of drugs on the basis of bilirubin-displacing effect on human serum albumin
  publication-title: Chem Pharm Bull.
  doi: 10.1248/cpb.32.2414
– volume: 22
  start-page: 1765
  year: 2001
  ident: 10.1016/j.clinthera.2009.11.019_bib19
  article-title: Comparative consistency between obesity determination standards using body mass index and ideal body weight
  publication-title: J Korean Acad Fam Med.
– volume: 71
  start-page: 214
  year: 2002
  ident: 10.1016/j.clinthera.2009.11.019_bib33
  article-title: Acute hypoxia and cytochrome P450-mediated hepatic drug metabolism in humans
  publication-title: Clin Pharmacol Ther.
  doi: 10.1067/mcp.2002.121789
– start-page: 153
  year: 1992
  ident: 10.1016/j.clinthera.2009.11.019_bib22
  article-title: Binding of drugs to biological material
– volume: 61
  start-page: 463
  year: 1980
  ident: 10.1016/j.clinthera.2009.11.019_bib4
  article-title: Richards lecture: Circulatory adjustments to hypoxia
  publication-title: Circulation
  doi: 10.1161/01.CIR.61.3.463
– year: 2007
  ident: 10.1016/j.clinthera.2009.11.019_bib23
– volume: 64
  start-page: 1309
  year: 1988
  ident: 10.1016/j.clinthera.2009.11.019_bib3
  article-title: Operation Everest II: Oxygen transport during exercise at extreme simulated altitude
  publication-title: J Appl Physiol.
  doi: 10.1152/jappl.1988.64.4.1309
– year: 1990
  ident: 10.1016/j.clinthera.2009.11.019_bib25
  article-title: Pharmacokinetics: The dynamics of drug absorption, distribution, and elimination
– volume: 43
  start-page: 85
  year: 2005
  ident: 10.1016/j.clinthera.2009.11.019_bib29
  article-title: Pharmacokinetics of prednisolone in man during acute and chronic exposure to high altitude
  publication-title: Int J Clin Pharmacol Ther.
  doi: 10.5414/CPP43085
– volume: 90
  start-page: 528
  year: 2001
  ident: 10.1016/j.clinthera.2009.11.019_bib27
  article-title: Enhanced synthesis of albumin and fibrinogen at high altitude
  publication-title: J Appl Physiol.
  doi: 10.1152/jappl.2001.90.2.528
– volume: 45
  start-page: 1277
  year: 1993
  ident: 10.1016/j.clinthera.2009.11.019_bib32
  article-title: Role of polymorphic and monomorphic human arylamine N-acetyltransferases in determining sulfamethoxazole metabolism
  publication-title: Biochem Pharmacol.
  doi: 10.1016/0006-2952(93)90280-A
– year: 2005
  ident: 10.1016/j.clinthera.2009.11.019_bib24
– volume: 15
  start-page: 51
  year: 1994
  ident: 10.1016/j.clinthera.2009.11.019_bib2
  article-title: Red blood cell function in hypoxia at altitude and exercise
  publication-title: Int J Sports Med.
  doi: 10.1055/s-2007-1021020
– volume: 163
  start-page: 402
  year: 2003
  ident: 10.1016/j.clinthera.2009.11.019_bib16
  article-title: Trimethoprim-sulfamethoxazole revisited
  publication-title: Arch Intern Med.
  doi: 10.1001/archinte.163.4.402
– volume: 46
  start-page: 90
  year: 1996
  ident: 10.1016/j.clinthera.2009.11.019_bib9
  article-title: The role of drugs in high altitude disorders
  publication-title: J Pak Med Assoc.
– volume: 38
  start-page: 533
  year: 1998
  ident: 10.1016/j.clinthera.2009.11.019_bib13
  article-title: Pharmacokinetics of acetazolamide in healthy volunteers after short- and long-term exposure to high altitude
  publication-title: J Clin Pharmacol.
  doi: 10.1002/j.1552-4604.1998.tb05791.x
– volume: 133
  start-page: 744
  year: 2008
  ident: 10.1016/j.clinthera.2009.11.019_bib8
  article-title: Medication and dosage considerations in the prophylaxis and treatment of high-altitude illness
  publication-title: Chest.
  doi: 10.1378/chest.07-1417
– volume: 7
  start-page: 562
  year: 2002
  ident: 10.1016/j.clinthera.2009.11.019_bib21
  article-title: Functions of the DAS software for pharmacologycal calculation
  publication-title: Chin J Clin Pharmacol Ther.
– volume: 45
  start-page: 1442
  year: 1966
  ident: 10.1016/j.clinthera.2009.11.019_bib26
  article-title: Metabolism of human serum albumin in man during acute exposure to high altitude (14,100 feet)
  publication-title: J Clin Invest.
  doi: 10.1172/JCI105452
– volume: 22
  start-page: viii
  year: 2004
  ident: 10.1016/j.clinthera.2009.11.019_bib7_2
  article-title: High altitude illness
  publication-title: Emerg Med Clin North Am.
  doi: 10.1016/j.emc.2004.02.001
– volume: 20
  start-page: 133
  year: 1998
  ident: 10.1016/j.clinthera.2009.11.019_bib14
  article-title: Urinary excretion of acetazolamide in healthy volunteers after short- and long-term exposure to high altitude
  publication-title: Methods Find Exp Clin Pharmacol.
  doi: 10.1358/mf.1998.20.2.485649
– volume: 48
  start-page: 167
  year: 1995
  ident: 10.1016/j.clinthera.2009.11.019_bib15
  article-title: Effects of altitude (4300 m) on the pharmacokinetics of caffeine and cardio-green in humans
  publication-title: Eur J Clin Pharmacol.
  doi: 10.1007/BF00192744
– volume: 25
  start-page: 527
  year: 2002
  ident: 10.1016/j.clinthera.2009.11.019_bib20
  article-title: The effect of rhodiola and acetazolamide on the sleep architecture and blood oxygen saturation in men living at high altitude
  publication-title: Zhonghua Jie He He Hu Xi Za Zhi
– volume: 247
  start-page: H251
  year: 1984
  ident: 10.1016/j.clinthera.2009.11.019_bib5
  article-title: Splanchnic vasomotor and metabolic adjustments to hypoxia and exercise in humans
  publication-title: AmJ Physiol.
– volume: 36
  start-page: 610
  year: 1996
  ident: 10.1016/j.clinthera.2009.11.019_bib10
  article-title: Pharmacokinetics of meperidine in healthy volunteers after short- and long-term exposure to high altitude
  publication-title: J Clin Pharmacol.
  doi: 10.1002/j.1552-4604.1996.tb04225.x
– volume: 18
  start-page: 49
  year: 1996
  ident: 10.1016/j.clinthera.2009.11.019_bib11
  article-title: Urinary excretion of meperidine and normeperedine in man upon acute and chronic exposure to high altitude
  publication-title: Methods Find Exp Clin Pharmacol.
– volume: 11
  start-page: 372
  year: 1986
  ident: 10.1016/j.clinthera.2009.11.019_bib17
  article-title: Clinical pharmacokinetics of cotrimazine
  publication-title: Clin Pharmacokinet.
  doi: 10.2165/00003088-198611050-00003
– volume: 17
  start-page: 348
  year: 2001
  ident: 10.1016/j.clinthera.2009.11.019_bib18
  article-title: Pharmacokinetic study of sulfamethoxazole and N4-acetylsulfamethoxazol
  publication-title: Chin J Clin Pharmacol.
SSID ssj0003952
Score 2.08753
Snippet Background: Sulfamethoxazole is an antibacterial sulfonamide used primarily for the treatment of a wide variety of bacterial infections in combination with...
Abstract Background: Sulfamethoxazole is an antibacterial sulfonamide used primarily for the treatment of a wide variety of bacterial infections in combination...
Sulfamethoxazole is an antibacterial sulfonamide used primarily for the treatment of a wide variety of bacterial infections in combination with trimethoprim....
Background_ Sulfamethoxazole is an antibacterial sulfonamide used primarily for the treatment of a wide variety of bacterial infections in combination with...
SourceID proquest
pubmed
pascalfrancis
crossref
elsevier
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 2744
SubjectTerms Altitude
Anti-Infective Agents - administration & dosage
Anti-Infective Agents - pharmacokinetics
Biological and medical sciences
Biotransformation
Blood
Blood Chemical Analysis
Blood Proteins - metabolism
China
Cytochrome
Drugs
Erythrocytes - metabolism
healthy volunteers
high altitude
Humans
Hypoxia
Hypoxia - metabolism
Internal Medicine
Male
Medical Education
Medical sciences
Metabolism
Metabolites
Pharmacokinetics
Pharmacology. Drug treatments
Prospective Studies
Protein Binding
sulfamethoxazole
Sulfamethoxazole - administration & dosage
Sulfamethoxazole - analogs & derivatives
Sulfamethoxazole - blood
Sulfamethoxazole - pharmacokinetics
Young Adult
SummonAdditionalLinks – databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3da9RAEF-0gggiWr-itcyD9OkCSTa3yfZFSrEUodKHE-4tbLK7UE2TaBLs-Q_7bziz-TgOqvU1yWw22dnZ-fwNY--LJUUJk8jnheZ-HJrYz1Gx8DWXwqbCyNiB-lx8Fudf4k_r5Xp0uLVjWuUkE52g1nVBPnLc3ZyHFOORH5rvPnWNoujq2ELjPnsQoqpCXJ2sZ4Mr4NJ13CErwI9kmO7kd1HloatxGkArCcqT4HZuP50eN6rFf2aHZhd_10bdqXT2lD0Z1Uk4Gdb_Gbtnqn328GIMmO-zo8sBmnqzgNW20qpdwBFcbkGrN8_Z79O5ISHUFnDK0IwPfMORiIiut31ples6faN-1aWBqwqu8YwBSsk0rQGSdrhWqFSC6qCsf4KiCt9eG1CVBlX0nQFz09TkmYSuBsJL3j5DSSJ9i6_JyT_UQnlFDg8c3UH4qrLc0LA7NMdwglNuTOUjQ5tyAWP2fWn0AvAHTrWk4JB0X7DV2cfV6bk_NoHwiyWXnZ_mSaxzLQyFBBVPZGSEFWmhQ6WU1YFNea5yHqHmu6SKLCXRArLBspBxwbXlL9leVVfmNYPCoDFoAiMomGhCrRLLba5sFOYmCaX1mJjWPitGgHTq01FmUybc12xmGmrfKdF8ypBpPBbMhM2AEXI3SToxVzaVwKLQzvAcu5s0uY3UtKPwabMwa6MscHl7ktg-kCSqJffY8Uw56leD3vR_rz3c2QPzl5ILERU94bGDaVNk26nMu9ZjMN9GCUZhKVWZum-zhPNUiDRNPfZq2EvbsR2iYSje_Hvst-yRC_K5EtEDttf96M071BW7_NAJhD8A9m_b
  priority: 102
  providerName: ProQuest
Title Comparison of the pharmacokinetics of sulfamethoxazole in male chinese volunteers at low altitude and acute exposure to high altitude versus subjects living chronically at high altitude: An open-label, controlled, prospective study
URI https://www.clinicalkey.com/#!/content/1-s2.0-S0149291809004093
https://www.clinicalkey.es/playcontent/1-s2.0-S0149291809004093
https://dx.doi.org/10.1016/j.clinthera.2009.11.019
https://www.ncbi.nlm.nih.gov/pubmed/20110016
https://www.proquest.com/docview/1033158289
https://www.proquest.com/docview/733866888
Volume 31
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVESC
  databaseName: Elsevier SD Complete Freedom Collection [SCCMFC]
  customDbUrl:
  eissn: 1879-114X
  dateEnd: 20131231
  omitProxy: true
  ssIdentifier: ssj0003952
  issn: 0149-2918
  databaseCode: ACRLP
  dateStart: 19950101
  isFulltext: true
  titleUrlDefault: https://www.sciencedirect.com
  providerName: Elsevier
– providerCode: PRVESC
  databaseName: Elsevier SD Freedom Collection
  customDbUrl:
  eissn: 1879-114X
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0003952
  issn: 0149-2918
  databaseCode: .~1
  dateStart: 19950101
  isFulltext: true
  titleUrlDefault: https://www.sciencedirect.com
  providerName: Elsevier
– providerCode: PRVESC
  databaseName: Elsevier SD Freedom Collection Journals [SCFCJ]
  customDbUrl:
  eissn: 1879-114X
  dateEnd: 20131231
  omitProxy: true
  ssIdentifier: ssj0003952
  issn: 0149-2918
  databaseCode: AIKHN
  dateStart: 19950101
  isFulltext: true
  titleUrlDefault: https://www.sciencedirect.com
  providerName: Elsevier
– providerCode: PRVLSH
  databaseName: Elsevier Journals
  customDbUrl:
  mediaType: online
  eissn: 1879-114X
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0003952
  issn: 0149-2918
  databaseCode: AKRWK
  dateStart: 19950101
  isFulltext: true
  providerName: Library Specific Holdings
– providerCode: PRVPQU
  databaseName: Health & Medical Collection
  customDbUrl:
  eissn: 1879-114X
  dateEnd: 20250801
  omitProxy: true
  ssIdentifier: ssj0003952
  issn: 0149-2918
  databaseCode: 7X7
  dateStart: 20020101
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/healthcomplete
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Central
  customDbUrl: http://www.proquest.com/pqcentral?accountid=15518
  eissn: 1879-114X
  dateEnd: 20250801
  omitProxy: true
  ssIdentifier: ssj0003952
  issn: 0149-2918
  databaseCode: BENPR
  dateStart: 20020101
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3di9NAEF-OE0QQ0fOrepZ5kHtqbNNNN8m91XJHVa4UqdC3sEl2oRqTYBK8-uC_67_hzOaL4skJviSQ7my2m9mZ2Z2Z3zD2OpqRl9CdWjyKueXYyrFCNCysmPtCe0L5jgH1uVqJ5Sfn_Xa2PWKLNheGwiob2V_LdCOtmyfjZjbH-W43prAk1O2EP0Wc6BPiJ6F_IU-_-dmHeXDfVN2hxha1PojxouxDk-dUA1cSnCdB7tysoe7nssB503XBi79bpEYzXT5kDxqTEub1qB-xI5WesLtXjdP8hJ2ta3jq_Qg2fbZVMYIzWPfA1fvH7NeiK0oImQYcMuRNgy_YExHR86JKtDSVp6_ljyxRsEvhK-oZoLBMVSggiYffCw1LkCUk2XeQlOVbxQpkGoOMqlKBus4zOp2EMgPCTO7bUKBIVeBrQjojKiDZ0aEH9m5gfGWS7KnbA5pzmOOQc5VayNQqGUETgZ-oeAQ4gW0-KRg03Sdsc3mxWSytphCEFc24X1pe6DpxGAtFbkHJXX-qhBZeFNtSSh1PtMdDGfIpWr8zysqSPu6C9GQW-U7EY82fsuM0S9VzBpHCDaGaKEEORWXH0tVch1JP7VC5tq8HTLTfPogakHSq1ZEEbTTc56BjGirh6eMWKkCmGbBJR5jXOCG3k3gtcwVtGiwK7gB12e2k7k2kqmgEUBHYQTENJsEfi2TAzjvKg3X2b68dHqyB7p_SMSIae2LATttFEfRDmXBuk3cW6aH7GaUYuaZkqrKqCFzOPSE8zxuwZ_Va6vs2qIa2ePE_I3_J7hk3oEkiPWXH5bdKvUJrsgyHRlzg1d26Q3Zn_u7DcoX3txer9cffXmR-4Q
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEF6VIgESQlBehlLmAD3Fku11bG8lhKpCldKm6iFIua3W9q5UMHbAidrwn_hd_A1m1o8oUqFcek0848fOa3dmvmHsTTakLGEcuDzLuRv6OnRTDCzcnIvIJJEWoQX1GZ9Go8_hp-lwusF-db0wVFbZ2URrqPMqozNy1G7OfcrxiPez7y5NjaLsajdCoxGLY728wC1b_e7oA67v2yA4_Dg5GLntVAE3G3Ixd5M0DvM0jzTlmBSPRaAjEyVZ7iulTO6ZhKcq5QGGUkNq8VECQ2rjDTMRZjw3HNneYrdDju-I6hNP-_2dx4Ud8EObDjcQfrJWTkaNjralqsHIJORQQve52hnen6kal8g0szX-HvxaJ3j4kD1oo1fYb8TtEdvQ5Ra7M27z81ts96xBwl4OYLJq7KoHsAtnK4zs5WP2-6CffwiVAXxkmLUXfEVORES_14vCKDvk-lL9rAoN5yV8Q5cGVAGqaw1kXFE0MIYFNYeiugBFDcWLXIMqc1DZYq5BX84qOgiFeQUEz7y6hmpSFjXeJqXjqBqKczpfQe4WMVgVxZLYrtHswT4-8kyXLuqPLgbQFvsXOh8AfsCudRUscO8TNrkJ6XjKNsuq1M8ZZBr3ntrTEeUutZ-r2HCTKhP4qY59YRwWdWsvsxaPncaCFLIrvPsie6GhaaECd2sShcZhXk84ayBJridJOuGSXcct-giJbvN60vgqUl23tq6WvqwD6dkyQUFi7wnyDII7bK-nbMO5Jkz7v9vurOlA_6Z0YolxZeSw7U4p5OpReiPhMOj_RoNJWTBV6mpRy5jzJIqSJHHYs0aXVrwtgKIfvfg379fs7mgyPpEnR6fHL9k9m1-03anbbHP-Y6FfYZg6T3escQAmb9gY_QHRM6x5
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3NbtNAEF6VIlVICEGBYihlDtBTLGyvY3srIVS1RC2lVQ5B6m21tnelgrENdtSGN-OJeA1m_BdFKpRLr4lnvMnOzszOzzeMvU7GlCUMPZsnKbd9V_t2jI6FnXIRmCjQwm9AfU7PgqPP_sfz8fka-9X3wlBZZa8TG0WdFgnFyPF0c-5Sjke8NV1ZxPRw8r78btMEKcq09uM0WhE50YtLvL5V744Pca_feN7kw-zgyO4mDNjJmIvajuLQT-M00JRvUjwUng5MECWpq5QyqWMiHquYe-hWjandRwl0r40zToSf8NRwZHuH3Q25z6maLDwf7noOF82wH7qA2J5wo5XSMmp6bNqrWrxMQhElpJ_rDeP9UlW4Xaads_F3R7gxiJOH7EHnycJ-K3qP2JrON9nGaZer32S70xYVezGC2bLJqxrBLkyXeNmLx-z3wTALEQoDuGQouwe-Iicios-reWZUM_D6Sv0sMg0XOXxD8wZUDaorDaRoUUzQnwVVQ1ZcgqLm4nmqQeUpqGRea9BXZUFBUagLIKjm5TNUnzKv8DUxhaYqyC4o1oLcG_RglWULYrtCswf7uORS5zaeJZ2NoCv8z3Q6AvwD-zZWaEB8n7DZbUjHU7aeF7l-xiDReA_Vjg4oj6ndVIWGm1gZz4116ApjsaDfe5l02Ow0IiSTfRHeFzkIDU0OFXhzkyg0FnMGwrKFJ7mZJOqFS_bdt2gvJJrQm0nD60h11em9Srqy8qTTlAwKEntHkJUQ3GJ7A2Xn2rUu2_-9dmflDAy_lKKX6GMGFtvuD4VcLmVQGBaD4WtUnpQRU7ku5pUMOY-CIIoii221Z2nJuwFTdIPn_-b9im2gGpKfjs9OXrB7FD9pS_q32Xr9Y65fosdaxzuNbgAmb1kX_QGnjLCu
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Comparison+of+the+Pharmacokinetics+of+Sulfamethoxazole+in+Male+Chinese+Volunteers+at+Low+Altitude+and+Acute+Exposure+to+High+Altitude+Versus+Subjects+Living+Chronically+at+High+Altitude%3A+An+Open-Label%2C+Controlled%2C+Prospective+Study&rft.jtitle=Clinical+therapeutics&rft.au=LI%2C+Xiang-Yang&rft.au=FEN+GAO&rft.au=LI%2C+Zhan-Quan&rft.au=WEI+GUAN&rft.date=2009-11-01&rft.pub=Elsevier&rft.issn=0149-2918&rft.volume=31&rft.issue=11&rft.spage=2744&rft.epage=2754&rft_id=info:doi/10.1016%2Fj.clinthera.2009.11.019&rft.externalDBID=n%2Fa&rft.externalDocID=22280246
thumbnail_m http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F01492918%2FS0149291809X00184%2Fcov150h.gif